---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-082956"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T08:47:39.017378+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CorMedix completes $300M acquisition of Melinta; raises FY2025 revenue guidance

## Summary
- Acquisition closed Aug 29, 2025; $260M cash + $40M equity upfront, plus up to $25M in milestone payments.
- Pro forma 2025 revenue guidance raised to $325-350M; synergies expected $35-45M annually.
- Transaction expected near-term accretive to EPS with double-digit accretion in 2026.
- Susan Blum appointed CFO, Elizabeth Hurlburt COO, Matthew David CBO effective immediately.
- Contingent payments include tiered royalties on REZZAYO US net sales and low-single-digit royalties on MINOCIN US net sales.

## SEC filing metadata
- accession: 0001213900-25-082956
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390025082956/0001213900-25-082956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390025082956/ea0255371-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-082956
- JSON: https://secwatch.observer/filing/0001213900-25-082956.json
- Plain text: https://secwatch.observer/filing/0001213900-25-082956.txt

## Key facts
- M&A Transactions
  CorMedix Inc. underwent a change of control involving Melinta Therapeutics, LLC for $260 million in cash and $40 million worth of common shares (closed 2025-08-29).
  - Action: change of control
  - Counterparty: Melinta Therapeutics, LLC
  - Consideration: $260 million in cash and $40 million worth of common shares
  - Closing: 2025-08-29
  source text: at the effective time of the Merger (the “Effective Time”), the Company (i) paid to the Melinta equityholders (including the Consenting Melinta Members) an aggregate of $260 million in cash (subject to adjustment for the Aggregate Exercise Price, Estimated Company Cash, Estimated Company Debt, Estimated Working Capital as compared to the Working Capital
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390025082956/0001213900-25-082956-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.